AU2005318369B2 - mRNA ratios in urinary sediments and/or urine as a prognostic and/or theranostic marker for prostate cancer - Google Patents

mRNA ratios in urinary sediments and/or urine as a prognostic and/or theranostic marker for prostate cancer Download PDF

Info

Publication number
AU2005318369B2
AU2005318369B2 AU2005318369A AU2005318369A AU2005318369B2 AU 2005318369 B2 AU2005318369 B2 AU 2005318369B2 AU 2005318369 A AU2005318369 A AU 2005318369A AU 2005318369 A AU2005318369 A AU 2005318369A AU 2005318369 B2 AU2005318369 B2 AU 2005318369B2
Authority
AU
Australia
Prior art keywords
pca3
prostate
nucleic acid
prostate cancer
specific
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU2005318369A
Other languages
English (en)
Other versions
AU2005318369A1 (en
Inventor
Daphne Hessels
Jack A. Schalken
Gerald Verhaegh
Alfred J. Witjes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stichting Radboud Universitair Medisch Centrum
Original Assignee
Stichting Katholieke Universiteit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stichting Katholieke Universiteit filed Critical Stichting Katholieke Universiteit
Publication of AU2005318369A1 publication Critical patent/AU2005318369A1/en
Application granted granted Critical
Publication of AU2005318369B2 publication Critical patent/AU2005318369B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
    • G01N2333/96455—Kallikrein (3.4.21.34; 3.4.21.35)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2005318369A 2004-12-24 2005-12-23 mRNA ratios in urinary sediments and/or urine as a prognostic and/or theranostic marker for prostate cancer Expired AU2005318369B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CA2,491,067 2004-12-24
CA002491067A CA2491067A1 (en) 2004-12-24 2004-12-24 Mrna rations in urinary sediments and/or urine as a prognostic marker for prostate cancer
US71955705P 2005-09-23 2005-09-23
US60/719,557 2005-09-23
PCT/EP2005/014021 WO2006066965A2 (en) 2004-12-24 2005-12-23 Mrna ratios in urinary sediments and/or urine as a prognostic and/or theranostic marker for prostate cancer

Publications (2)

Publication Number Publication Date
AU2005318369A1 AU2005318369A1 (en) 2006-06-29
AU2005318369B2 true AU2005318369B2 (en) 2012-02-09

Family

ID=36636708

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005318369A Expired AU2005318369B2 (en) 2004-12-24 2005-12-23 mRNA ratios in urinary sediments and/or urine as a prognostic and/or theranostic marker for prostate cancer

Country Status (12)

Country Link
US (8) US7960109B2 (https=)
EP (3) EP1761651B1 (https=)
JP (1) JP4944041B2 (https=)
AT (1) ATE457362T1 (https=)
AU (1) AU2005318369B2 (https=)
CA (2) CA2491067A1 (https=)
DE (1) DE602005019294D1 (https=)
DK (1) DK1761651T3 (https=)
ES (2) ES2340513T3 (https=)
IL (1) IL183476A0 (https=)
WO (1) WO2006066965A2 (https=)
ZA (1) ZA200703746B (https=)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
DE69840669D1 (de) 1997-04-10 2009-04-30 Stichting Katholieke Univ Pca3, pca3-gene und verfahren zu ihrer verwendung
EP1222266B1 (en) 1999-09-29 2006-03-29 Diagnocure Inc. Pca3 messenger rna in benign and malignant prostate tissues
EP1592809B1 (en) 2003-02-07 2013-04-10 Diagnocure Inc. Method to detect prostate cancer in a sample
US11105808B2 (en) 2004-11-12 2021-08-31 Health Discovery Corporation Methods for screening, predicting and monitoring prostate cancer
CA2491067A1 (en) 2004-12-24 2006-06-24 Stichting Katholieke Universiteit Mrna rations in urinary sediments and/or urine as a prognostic marker for prostate cancer
CA2646329C (en) 2006-03-20 2018-07-03 The Regents Of The University Of California Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting
JP4943074B2 (ja) * 2006-07-03 2012-05-30 シスメックス株式会社 がん転移の判定方法及び装置
WO2009032949A2 (en) 2007-09-04 2009-03-12 The Regents Of The University Of California High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection
WO2009085196A1 (en) * 2007-12-21 2009-07-09 Wake Forest University Health Sciences Methods and compositions for correlating genetic markers with prostate cancer risk
GB2465088C (en) * 2008-10-30 2016-01-27 Caris Mpi Inc miRNA expression in the characterisation and classification of cancer
US7888035B2 (en) 2008-10-30 2011-02-15 Caris Mpi, Inc. Methods for assessing RNA patterns
WO2010056337A2 (en) * 2008-11-12 2010-05-20 Caris Mpi, Inc. Methods and systems of using exosomes for determining phenotypes
ES2712732T3 (es) 2009-02-17 2019-05-14 Cornell Res Foundation Inc Métodos y kits para el diagnóstico de cáncer y la predicción de valor terapéutico
JP2010233542A (ja) * 2009-03-31 2010-10-21 Kanazawa Univ Ｒａｇｅ遺伝子の２種類のスプライシングバリアントを区別して増幅可能なプライマーセット及びプローブ
EP2320234A1 (en) 2009-11-06 2011-05-11 IMG Institut für medizinische Genomforschung Planungsgesellschaft M.B.H. Marker combination for prostate cancer diagnosis
EP2320235A1 (en) 2009-11-06 2011-05-11 IMG Institut für medizinische Genomforschung Planungsgesellschaft M.B.H. Marker for prostate cancer diagnosis
AU2010325969B2 (en) 2009-12-02 2016-10-20 Imaginab, Inc. J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen
EP2542696B1 (en) 2010-03-01 2016-09-28 Caris Life Sciences Switzerland Holdings GmbH Biomarkers for theranostics
JP2013526852A (ja) 2010-04-06 2013-06-27 カリス ライフ サイエンシズ ルクセンブルク ホールディングス 疾患に対する循環バイオマーカー
US9458663B2 (en) * 2010-04-16 2016-10-04 Hunter Douglas Inc. Process and system for manufacturing a roller blind
US9732389B2 (en) 2010-09-03 2017-08-15 Wake Forest University Health Sciences Methods and compositions for correlating genetic markers with prostate cancer risk
US20130288250A1 (en) * 2010-10-20 2013-10-31 Universite Bordeaux Segalen Signatures of clinical outcome in gastro intestinal stromal tumors and method of treatment of gastrointestinal stromal tumors
US9534256B2 (en) 2011-01-06 2017-01-03 Wake Forest University Health Sciences Methods and compositions for correlating genetic markers with risk of aggressive prostate cancer
EP3492606B1 (en) * 2011-08-22 2023-10-04 Exosome Diagnostics, Inc. Urine biomarkers
EP2574929A1 (en) 2011-09-28 2013-04-03 IMG Institut für medizinische Genomforschung Planungsgesellschaft M.B.H. Marker in diagnosing prostate cancer (PC)
CA2920429C (en) * 2013-08-06 2021-11-16 Exosome Diagnostics, Inc. Urine biomarker cohorts, gene expression signatures, and methods of use thereof
US10364469B2 (en) 2014-01-16 2019-07-30 Illumina, Inc Gene expression panel for prognosis of prostate cancer recurrence
US9994912B2 (en) 2014-07-03 2018-06-12 Abbott Molecular Inc. Materials and methods for assessing progression of prostate cancer
CN107250375A (zh) 2014-11-06 2017-10-13 科罗拉多州立大学董事会 在血栓溶解剂存在下使用粘弹性分析鉴定新疾病状态
US11187710B2 (en) 2015-06-08 2021-11-30 The Regents Of The University Of Colorado, A Body Corporate Time independent viscoelastic analysis parameter for prediction of patient outcome
US11254744B2 (en) 2015-08-07 2022-02-22 Imaginab, Inc. Antigen binding constructs to target molecules
US11871895B2 (en) 2015-11-24 2024-01-16 The Johns Hopkins University Raman spectroscopy reporters and methods for molecular imaging of tissue in vivo
EP3455366A4 (en) 2016-05-11 2020-02-26 Michael P. Chapman ANALYSIS OF VISCOELASTICITY IN PATIENTS WITH A DISEASE ASSOCIATED WITH THE CARDIOVASCULAR SYSTEM
CN109072293A (zh) * 2016-05-13 2018-12-21 豪夫迈·罗氏有限公司 Met外显子14缺失的检测和相关疗法
US11266745B2 (en) 2017-02-08 2022-03-08 Imaginab, Inc. Extension sequences for diabodies
WO2019093530A1 (ja) * 2017-11-13 2019-05-16 株式会社リコー 検出判定用デバイス
US11530451B2 (en) 2018-03-02 2022-12-20 The Johns Hopkins University Methods for prostate cancer detection
CN110423797A (zh) * 2019-07-11 2019-11-08 杨海涛 一种前列腺癌pca3基因双重实时pcr的引物、方法及试剂盒
CN114743593B (zh) * 2022-06-13 2023-02-24 北京橡鑫生物科技有限公司 一种基于尿液进行前列腺癌早期筛查模型的构建方法、筛查模型及试剂盒

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2422956A1 (fr) * 1978-04-13 1979-11-09 Pasteur Institut Procede de detection et de caracterisation d'un acide nucleique ou d'une sequence de celui-ci, et reactif enzymatique pour la mise en oeuvre de ce procede
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4690890A (en) 1984-04-04 1987-09-01 Cetus Corporation Process for simultaneously detecting multiple antigens using dual sandwich immunometric assay
US4786600A (en) 1984-05-25 1988-11-22 The Trustees Of Columbia University In The City Of New York Autocatalytic replication of recombinant RNA
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4965188A (en) * 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
DE3689123T2 (de) 1985-11-01 1994-03-03 Xoma Corp Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung.
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US4851331A (en) * 1986-05-16 1989-07-25 Allied Corporation Method and kit for polynucleotide assay including primer-dependant DNA polymerase
FR2602592B1 (fr) 1986-08-06 1989-06-30 Alain Baret Utilisation du systeme enzymatique xanthine-oxydase en immuno-analyse, procedes de dosage correspondants et coffrets de reactifs necessaires pour la mise en oeuvre de ces procedes.
US5541308A (en) * 1986-11-24 1996-07-30 Gen-Probe Incorporated Nucleic acid probes for detection and/or quantitation of non-viral organisms
US5202231A (en) * 1987-04-01 1993-04-13 Drmanac Radoje T Method of sequencing of genomes by hybridization of oligonucleotide probes
US5149625A (en) * 1987-08-11 1992-09-22 President And Fellows Of Harvard College Multiplex analysis of DNA
US5283174A (en) 1987-09-21 1994-02-01 Gen-Probe, Incorporated Homogenous protection assay
US5585481A (en) * 1987-09-21 1996-12-17 Gen-Probe Incorporated Linking reagents for nucleotide probes
US5639604A (en) * 1987-09-21 1997-06-17 Gen-Probe Incorporated Homogeneous protection assay
CA1323293C (en) 1987-12-11 1993-10-19 Keith C. Backman Assay using template-dependent nucleic acid probe reorganization
US5002867A (en) * 1988-04-25 1991-03-26 Macevicz Stephen C Nucleic acid sequence determination by multiple mixed oligonucleotide probes
NL8801147A (nl) * 1988-05-02 1989-12-01 Tno Werkwijze voor het detecteren van genetische variatie, en daarvoor geschikte kit.
DK167254B1 (da) 1988-07-21 1993-09-27 Hartmann As Brdr Fremgangsmaade til fremstilling af formede genstande af et fluidiseret cellulosefibermateriale
US5183949A (en) * 1988-09-22 1993-02-02 The United States Of America As Represented By The Department Of Health And Human Services Rabbit model for diagnosing and testing vaccines or therapeutic agents against aids
US5118801A (en) 1988-09-30 1992-06-02 The Public Health Research Institute Nucleic acid process containing improved molecular switch
US5219989A (en) 1988-12-13 1993-06-15 Mcgill University Bifunctional protein for the isolation of capped mRNA
US5082670A (en) * 1988-12-15 1992-01-21 The Regents Of The University Of California Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system
US5175383A (en) * 1989-02-17 1992-12-29 President And Fellows Of Harvard College Animal model for benign prostatic disease
US5112736A (en) 1989-06-14 1992-05-12 University Of Utah Dna sequencing using fluorescence background electroblotting membrane
US5656207A (en) * 1989-06-24 1997-08-12 Gen Probe Incorporated Detecting or quantifying multiple analytes using labelling techniques
US5174986A (en) * 1989-07-05 1992-12-29 Genpharm International, Inc. Method for determining oncogenic potential of a chemical compound
CA2020958C (en) * 1989-07-11 2005-01-11 Daniel L. Kacian Nucleic acid sequence amplification methods
IE911869A1 (en) 1990-06-01 1991-12-04 Regeneron Pharma A family of map2 protein kinases
AU662906B2 (en) 1991-06-26 1995-09-21 F. Hoffmann-La Roche Ag Methods for detection of carcinoma metastases by nucleic acid amplification
EP0558697A1 (en) * 1991-06-28 1993-09-08 Massachusetts Institute Of Technology Localized oligonucleotide therapy
AU2468992A (en) 1991-08-16 1993-03-16 General Hospital Corporation, The Method of gene delivery to post-mitotic cells
WO1993008845A1 (en) 1991-11-08 1993-05-13 Massachusetts Institute Of Technology Localized oligonucleotide therapy
EP0618972A1 (en) * 1991-12-16 1994-10-12 E.I. Du Pont De Nemours And Company CONSTITUTIVE EXPRESSION OF P450SOY AND FERREDOXIN-SOY IN $i(STREPTOMYCES), AND BIOTRANSFORMATION OF CHEMICALS BY RECOMBINANT ORGANISMS
JP3131222B2 (ja) 1991-12-24 2001-01-31 アイシス・ファーマシューティカルス・インコーポレーテッド ギャップを有する２′修飾オリゴヌクレオチド
KR100249110B1 (ko) 1992-05-06 2000-04-01 다니엘 엘. 캐시앙 핵산 서열 증폭 방법, 이에 이용되는 조성물 및 키트
US5674682A (en) * 1992-10-29 1997-10-07 Thomas Jefferson University Nucleic acid primers for detecting micrometastasis of prostate cancer
DE69334071T2 (de) 1992-11-05 2007-10-25 Sloan-Kettering Institute For Cancer Research Prostata-spezifisches membranantigen
US5503980A (en) 1992-11-06 1996-04-02 Trustees Of Boston University Positional sequencing by hybridization
US5773705A (en) * 1992-12-31 1998-06-30 Wisconsin Alumni Research Foundation Ubiquitin fusion protein system for protein production in plants
DE69429087T2 (de) 1993-01-07 2002-07-11 Thomas Jefferson University, Philadelphia Modulation der proliferation von glatten muskelzellen durch antisense inhibition von c-myc
US5422252A (en) * 1993-06-04 1995-06-06 Becton, Dickinson And Company Simultaneous amplification of multiple targets
US5861242A (en) 1993-06-25 1999-01-19 Affymetrix, Inc. Array of nucleic acid probes on biological chips for diagnosis of HIV and methods of using the same
US5837832A (en) 1993-06-25 1998-11-17 Affymetrix, Inc. Arrays of nucleic acid probes on biological chips
US6323184B1 (en) 1993-10-15 2001-11-27 Thomas Jefferson University Arteriovenous and venous graft treatments: methods and compositions
US5925517A (en) 1993-11-12 1999-07-20 The Public Health Research Institute Of The City Of New York, Inc. Detectably labeled dual conformation oligonucleotide probes, assays and kits
WO1995025180A1 (en) 1994-03-16 1995-09-21 Gen-Probe Incorporated Isothermal strand displacement nucleic acid amplification
CA2187775A1 (en) 1994-04-15 1995-10-26 Aaron E. Katz Method for molecular staging of prostate cancer
JPH10500310A (ja) 1994-05-19 1998-01-13 ダコ アクティーゼルスカブ 淋菌及びトラコーマ クラミジアの検出のためのｐｎａ プローブ
WO1996011266A2 (en) 1994-10-05 1996-04-18 Amgen Inc. Method for inhibiting smooth muscle cell proliferation and oligonucleotides for use therein
DE69535240T2 (de) 1994-10-28 2007-06-06 Gen-Probe Inc., San Diego Zusammensetzungen und Verfahren für die gleichzeitige Detektion und Quantifizierung von einer Mehrheit spezifischer Nuklein Säure Sequenzen
US5919652A (en) 1994-11-09 1999-07-06 The Regents Of The University Of California Nucleic acid molecules comprising the prostate specific antigen (PSA) promoter and uses thereof
DE19513152A1 (de) * 1995-04-07 1996-10-10 Bundesrep Deutschland Verwendung eines "Immundefizienzvirus-supprimierenden Lymphokins (ISL)" zur Hemmung der Virusvermehrung, insbesondere von Retroviren
US5731148A (en) 1995-06-07 1998-03-24 Gen-Probe Incorporated Adduct protection assay
JP2000514307A (ja) 1996-07-16 2000-10-31 ジェン―プローブ・インコーポレーテッド 増加した標的特異的ｔ▲下ｍ▼を持つ修飾オリゴヌクレオチドを用いた核酸配列の検出および増幅のための方法
US6479263B1 (en) * 1996-11-14 2002-11-12 Baylor College Of Medicine Method for detection of micrometastatic prostate cancer
PL196260B1 (pl) * 1997-02-25 2007-12-31 Corixa Corp Polipeptyd, cząsteczka DNA, komórka gospodarza, białko fuzyjne, kompozycje farmaceutyczne i szczepionki do leczenia raka prostaty
US6465611B1 (en) * 1997-02-25 2002-10-15 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
US6395278B1 (en) * 1997-02-25 2002-05-28 Corixa Corporation Prostate specific fusion protein compositions
US6800746B2 (en) * 1997-02-25 2004-10-05 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6261562B1 (en) * 1997-02-25 2001-07-17 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
DE69840669D1 (de) 1997-04-10 2009-04-30 Stichting Katholieke Univ Pca3, pca3-gene und verfahren zu ihrer verwendung
EP0975807B1 (en) * 1997-05-02 2006-09-27 Gen-Probe Incorporated Two-step hybridization and capture of a polynucleotide
US6534273B2 (en) * 1997-05-02 2003-03-18 Gen-Probe Incorporated Two-step hybridization and capture of a polynucleotide
CA2288789C (en) * 1997-05-08 2009-07-21 Merck Sharp & Dohme Limited Substituted 1,2,4-triazolo[3,4-a]phthalazine derivatives as gaba alpha 5 ligands
US6251638B1 (en) * 1997-05-30 2001-06-26 Diagen Corporation Methods for detection of nucleic acid sequences in urine
US20020035244A1 (en) * 1997-09-09 2002-03-21 Maurice Cohen Reagents and methods useful for detecting diseases of the prostate
US6124120A (en) 1997-10-08 2000-09-26 Yale University Multiple displacement amplification
US6200765B1 (en) * 1998-05-04 2001-03-13 Pacific Northwest Cancer Foundation Non-invasive methods to detect prostate cancer
HUP0203035A3 (en) 1998-07-14 2007-12-28 Corixa Corp Compositions and methods for therapy and diagnosis of prostate cancer
US6037130A (en) 1998-07-28 2000-03-14 The Public Health Institute Of The City Of New York, Inc. Wavelength-shifting probes and primers and their use in assays and kits
EP1151142A2 (en) * 1999-01-28 2001-11-07 Gen-Probe Incorporated Nucleic acid sequences for detecting genetic markers for cancer in a biological sample
FI990382A0 (fi) 1999-02-23 1999-02-23 Arctic Partners Oy Ab Uusi diagnostinen menetelmä
US6528260B1 (en) * 1999-03-25 2003-03-04 Genset, S.A. Biallelic markers related to genes involved in drug metabolism
JP4942248B2 (ja) 1999-03-26 2012-05-30 ザ・ヘンリー・エム・ジャクソン・ファンデイション・フォー・ジ・アドヴァンスメント・オヴ・ミリタリー・メディシン、インコーポレイテッド 前立腺特異的遺伝子、ｐｃｇｅｍ１、ならびに前立腺癌を検出、治療および予防するための、ｐｃｇｅｍ１の使用方法
EP1222266B1 (en) * 1999-09-29 2006-03-29 Diagnocure Inc. Pca3 messenger rna in benign and malignant prostate tissues
WO2001025273A2 (en) 1999-10-04 2001-04-12 Corixa Corporation Compositions and methods for wt1 specific immunotherapy
WO2001025272A2 (en) 1999-10-04 2001-04-12 Corixa Corporation Compositions and methods for therapy and diagnosis of prostate cancer
AU1656501A (en) 1999-11-12 2001-06-06 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
ATE392486T1 (de) 1999-12-17 2008-05-15 Bio Merieux Verfahren zur markierung von nukleinsäuren
CA2397741A1 (en) 2000-01-14 2001-07-19 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US20020168638A1 (en) * 2000-01-24 2002-11-14 Robert Schlegel Compositions, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer
WO2001060860A2 (en) 2000-02-17 2001-08-23 Millennium Predictive Medicine, Inc. Genes differentially expressed in human prostate cancer and their use
CA2403909A1 (en) 2000-03-27 2001-10-04 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
FR2810114B1 (fr) 2000-06-13 2002-08-23 Bio Merieux Methode, procede, test immunologique et kit de diagnostic d'un adenocarcinome de la prostate ou d'une hypertrophie benigne de la prostate
AU2001292842A1 (en) 2000-09-19 2002-04-02 Diadexus, Inc. Compositions and methods relating to prostate specific genes and proteins
EP1474528A4 (en) 2000-10-13 2006-06-14 Protein Design Labs Inc METHODS OF DIAGNOSIS OF PROSTATE CANCER, COMPOSITIONS AND METHODS OF EXAMINING PROSTATE CANCER MODULATORS
US6897024B2 (en) * 2001-05-31 2005-05-24 Stichting Katholieke Universiteit More Particularly The University Medical Centre Nijmegen Nucleic acid molecules comprising the promoter for PCA3, and uses thereof
EP1592809B1 (en) * 2003-02-07 2013-04-10 Diagnocure Inc. Method to detect prostate cancer in a sample
CA2432365A1 (en) 2003-06-30 2004-12-30 Jack A. Schalken Specific method of prostate cancer detection based on pca3, and kits therefore
CA2491067A1 (en) * 2004-12-24 2006-06-24 Stichting Katholieke Universiteit Mrna rations in urinary sediments and/or urine as a prognostic marker for prostate cancer

Also Published As

Publication number Publication date
US8257924B2 (en) 2012-09-04
US20160362746A1 (en) 2016-12-15
JP4944041B2 (ja) 2012-05-30
DK1761651T3 (da) 2010-05-17
CA2594125A1 (en) 2006-06-29
ES2340513T3 (es) 2010-06-04
ES2546193T3 (es) 2015-09-21
WO2006066965A3 (en) 2006-10-26
US7960109B2 (en) 2011-06-14
EP2226394A1 (en) 2010-09-08
US20180223375A1 (en) 2018-08-09
US20130261171A1 (en) 2013-10-03
EP2325334A1 (en) 2011-05-25
US10752957B2 (en) 2020-08-25
EP2226394B1 (en) 2015-06-03
EP1761651B1 (en) 2010-02-10
CA2491067A1 (en) 2006-06-24
ATE457362T1 (de) 2010-02-15
EP1761651A2 (en) 2007-03-14
IL183476A0 (en) 2007-09-20
DE602005019294D1 (de) 2010-03-25
US20120309007A1 (en) 2012-12-06
HK1148315A1 (en) 2011-09-02
US20200392588A1 (en) 2020-12-17
US20120003640A1 (en) 2012-01-05
AU2005318369A1 (en) 2006-06-29
US20100021884A1 (en) 2010-01-28
US9951390B2 (en) 2018-04-24
US9096907B2 (en) 2015-08-04
CA2594125C (en) 2016-06-14
WO2006066965A2 (en) 2006-06-29
JP2008524998A (ja) 2008-07-17
US20150307948A1 (en) 2015-10-29
ZA200703746B (en) 2008-07-30

Similar Documents

Publication Publication Date Title
US10752957B2 (en) Prostate cancer prognostic compositions and kits
US11104958B2 (en) Method to detect prostate cancer in a sample
WO2006056080A1 (en) Gpx2 a specific and sensitive target for lung cancer diagnosis, prognosis and/or theranosis
WO2006053442A1 (en) Calml3 a specific and sensitive target for lung cancer diagnosis, prognosis and/or theranosis
HK1148315B (en) Mrna ratios in urinary sediments and/or urine as a prognostic and/or theranostic marker for prostate cancer

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired